0 224

Cited 0 times in

Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.

DC FieldValueLanguage
dc.contributor.author노성훈-
dc.contributor.author라선영-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.date.accessioned2016-05-16T11:01:09Z-
dc.date.available2016-05-16T11:01:09Z-
dc.date.issued2002-
dc.identifier.issn1107-3756-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/143607-
dc.description.abstractAmong the many biological characteristics of cancer, matrix-metalloproteinases (MMPs) are essential for tumor invasion and metastasis. To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9. Thirty-four paired normal and gastric cancer tissues were tested to measure the IC50 of the gabexate mesylate. MMP-9 activity was measured by zymography. Both MMP-9 expression (p=0.04) and IC50 (p=0.02) were higher in cancer than normal tissues. IC50 of the cancer tissues was higher than paired normal tissues especially in cases with large tumor (≥5 cm) (p=0.03), higher T-stage (p=0.04), lymph node metastasis (p=0.04) and advanced stage (p=0.04). In cancers extending beyond submucosa or in diffuse/mixed type, a tendency of higher IC50 was observed than tumors confined to submucosa or intestinal type cancer despite similar MMP-9 activity between the groups. Patients with high IC50 showed poorer prognosis than patients with low IC50 in curatively-resected group. In multivariate analysis, high IC50 was suggested as an independent prognostic factor. We were able to differentiate the high risk patients using IC50 of gabexate mesylate in ex vivo model. This model can be applied in detecting patients with poor prognosis and patients who may benefit from MMPI treatment.-
dc.description.statementOfResponsibilityopen-
dc.format.extent251~256-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF MOLECULAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAdenocarcinoma/surgery-
dc.subject.MESHAdult-
dc.subject.MESHAge Factors-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHCell Differentiation-
dc.subject.MESHEnzyme Inhibitors/pharmacology*-
dc.subject.MESHFemale-
dc.subject.MESHGabexate/pharmacology-
dc.subject.MESHHumans-
dc.subject.MESHInhibitory Concentration 50-
dc.subject.MESHMale-
dc.subject.MESHMatrix Metalloproteinase Inhibitors*-
dc.subject.MESHMatrix Metalloproteinases/pharmacology-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHPhenotype-
dc.subject.MESHPrognosis-
dc.subject.MESHSerine Proteinase Inhibitors/pharmacology-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/pathology*-
dc.subject.MESHStomach Neoplasms/surgery-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleBiological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.-
dc.typeArticle-
dc.contributor.collegeResearcher Institutes (부설 연구소)-
dc.contributor.departmentCancer Metastasis Research Center (암전이연구센터)-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorHei Cheul Jeung-
dc.contributor.googleauthorJae Kyung Roh-
dc.contributor.googleauthorJin Ju Kim-
dc.contributor.googleauthorSung Hoon Noh-
dc.contributor.googleauthorJin Sik Min-
dc.contributor.googleauthorByung Soo Kim-
dc.contributor.googleauthorHyun Cheol Chung-
dc.identifier.doi10.3892/ijmm.10.3.251-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01281-
dc.contributor.localIdA03773-
dc.contributor.localIdA01316-
dc.contributor.localIdA03794-
dc.relation.journalcodeJ01132-
dc.identifier.eissn1791-244X-
dc.identifier.pmid12165796-
dc.identifier.urlhttp://www.spandidos-publications.com/ijmm/10/3/251-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.rights.accessRightsnot free-
dc.citation.volume10-
dc.citation.number3-
dc.citation.startPage251-
dc.citation.endPage256-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, Vol.10(3) : 251-256, 2002-
Appears in Collections:
5. Research Institutes (연구소) > Cancer Metastasis Research Center (암전이연구센터) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.